Involvement of human and canine MRP1 and MRP4 in benzylpenicillin transport

Xiaofen Zhao†, Yangfang Li†, Kun Du†, Yuqin Wu†, Ling Liu†, Shan Cui†, Yan Zhang†, Jin Gao†, Richard F. Keep‡, Jianming Xiang*†

1 Department of Neonate, Kunming Children's Hospital, Kunming, China, 2 Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan, United States of America

‡ These authors are co-first authors on this work.
* jmxxdrnx@umich.edu

Abstract

The blood-brain barrier (BBB) is a dynamic and complex interface between blood and the central nervous system (CNS). It protects the brain by preventing toxic substances from entering the brain but also limits the entry of therapeutic agents. ATP-binding cassette (ABC) efflux transporters are critical for the functional barrier and present a formidable impediment to brain delivery of therapeutic agents including antibiotics. The aim of this study was to investigate the possible involvement of multidrug resistance-associated protein 1 and 4 (MRP1 and MRP4), two ABC transporters, in benzylpenicillin efflux transport using wild-type (WT) MDCKII cells and cells overexpressing those human transporters, as well as non-selective and selective inhibitors. We found that inhibiting MRP1 or MRP4 significantly increased [3H]benzylpenicillin uptake in MDCKII-WT, -MRP1 or –MRP4 cells. Similar results were also found in HepG2 cells, which highly express MRP1 and MRP4, and hCMEC/D3 cells which express MRP1. The results indicate that human and canine MRP1 and MRP4 are involved in benzylpenicillin efflux transport. They could be potential therapeutic targets for improving the efficacy of benzylpenicillin for treating CNS infections since both MRP1 and MRP4 express at human blood-brain barrier.

Introduction

Treating CNS disorders is a huge challenge because of the presence of the blood-brain barrier (BBB) which is a dynamic physical and biological barrier between blood circulation and the central nervous system (CNS). The unique features of the BBB lie in the structure/function of the cerebral microvascular endothelial cells and the neurovascular unit comprised of those cells and surrounding astrocytes, pericytes and extracellular matrix. It offers a unique protection to CNS by restricting the entry of toxin, pathogen and xenobiotics into brain and, at same time, it limits the delivery of therapeutic agents to the brain[1–3]. Unlike other organs of the human body, more than 98% of small molecules and almost 100% of large therapeutic molecules cannot reach the brain via the circulatory system. ABC (ATP-binding cassette) efflux transporters, expressed on the luminal (blood-facing) plasma membrane of brain capillary...
endothelial cells, are an important functional part of the BBB. They play a critical role in keeping drugs and neurotoxic substances from entering the brain and in transporting toxic metabolites out of the brain[4–6]. ABC efflux transporters include P-gp (P-glycoprotein), BCRP (breast cancer resistance protein) and MRPs (multidrug resistance proteins, ABCCs; which have 13 members), are known to be involved in exporting a wide range of drugs, such as antibiotics, anti-HIV drugs, anticancer agents, antihistamines, immunosuppressive drugs and analgesics, at the BBB[7–14]. They are a potential target and an innovative strategy in treating CNS diseases and protecting brain since changes in the transporter expression and transport activity can have a major effect on pharmacotherapy[15–19].

Beta-lactam antibiotics are a class of drugs consisting of all antibiotic agents that contain a beta-lactam ring in their molecular structure. This includes penicillins, cephalosporins, cephamycins, carbapenems and monobactams. Because of their wide spectrum and broad therapeutic index, they are among the most commonly prescribed antibiotics in treating bacterial infections, including those of the CNS[20, 21]. That includes neonatal purulent meningitis, which has a high mortality rate and causes neurological sequelae and lifelong impairment[22, 23]. Although uncommon, beta-lactam antibiotic toxicity is severe and antibiotic resistance also often develops[24, 25]. Benzylpenicillin penetration across the BBB is limited, but peripherally administered high dose benzylpenicillin can cause seizures[25, 26]. The mechanisms regulating benzylpenicillin entry into brain are still not clear, particularly regarding which ABC transporters may be involved in benzylpenicillin efflux at the human BBB. Previous studies have indicated that some beta-lactam antibiotics, such as benzylpenicillin, ceftriaxone and ampicillin, are substrates of P-gp, which might account for low brain penetration[27–30]. In contradiction, another study suggested that P-gp and BCRP are not involved in benzylpenicillin efflux transport in human[31]. Interestingly, our previous study has shown that benzylpenicillin is a substrate of human BCRP, but not P-gp[32]. However, it has not yet been reported if benzylpenicillin is a substrate of MRPs in human.

The aim of this study was to investigate if MRPs are involved in benzylpenicillin efflux transport in human. We focused on MRP1 and MRP4 because they express in human brain endothelial cells and selective inhibitors for them are commercially available.

Materials and methods

MDCKII-WT, MDCKII-MRP1 and MDCKII-MRP4 cells were obtained from Netherlands Cancer Institute (Dr. A. H. Schinkel), Amsterdam, Netherlands. Hep G2 cell was purchased from ATCC (Manassas, VA, USA). hCMEC/D3 cells were obtained from Dr. Pierre-Olivier Couraud (Institute Cochin, Paris, France). Cell culture medium and fetal bovine serum (FBS) was purchased from Thermo Fisher Scientific (Grand Island, NY, USA). The non-selective MRP inhibitor MK 571 was from Cayman Chemical (Ann Arbor, MI, USA) and selective MRP1 inhibitor reversan[33, 34] and selective MRP4 inhibitor ceefourin 1[35, 36] were from Sigma (St. Louis, MO, USA) and ABCAM (Cambridge, MA, USA). [3H]Benzylpenicillin (25 Ci/mmol) and [14C]mannitol (55 mCi/mmol) were purchased from American Radiolabeled Chemicals, Inc. (St. Louis, MO, USA).

Cell culture

For [3H]benzylpenicillin uptake experiments, MDCKII-WT, MDCKII-MRP1, MDCKII-MRP4 and Hep G2 were cultured in 12-well plates. As previously described[37], cells were grown in DMEM supplemented with 10% FBS in humidified incubator with 95% air-5% CO2 at 37˚C and the medium was changed every other day. hCMEC/D3 cells were cultured in DMEM-F12 supplemented with: 10% FBS, 15mM Hepes, 2mM glutamine, insulin: 5μg/ml,
EGF: 50ng/ml EGF, bFGF: 25ng/ml, hydrocortisone: 2μg/ml and transferrin: 5μg/ml. hCMEC/D3 were also grown in humidified incubator with 95% air-5% CO2 at 37˚C and the medium was changed every other day. All of cells were ready for uptake experiment when they reached 80–90% confluency.

[^3]H Benzylpenicillin uptake
[^3]H Benzylpenicillin uptake was examined in MDCKII-WT, MDCKII-MRP1, MDCKII-MRP4, Hep G2 and hCMEC/D3 cells. The culture medium was removed at the beginning of the experiment and the cells were washed once with DMEM. Then, 1ml of uptake medium (DMEM) containing 0.1μCi [^3]Hbenzylpenicillin and 0.05μCi [^14]Cmannitol (internal control), with or without inhibitors, was added to initiate uptake. After incubating at 37˚C for 1 hour[^32], the uptake medium was removed and the cells were rapidly washed with ice-cold PBS for three times. Hyamine hydroxide was used to lyse the cells and the cell lysis was counted in a liquid scintillation counter (Beckman Coulter LS6500). Uptake was expressed per mg cell protein and [^14]Cmannitol (about 5% of [^3]H Benzylpenicillin in the cells) was used to correct for extracellular contamination as described previously[^32].

Quantitative real time RT-PCR (qRT-PCR)

All of materials were from Thermo Fisher Scientific (Grand Island, NY, USA), unless otherwise stated. Total RNA was extracted from the cells using TRIzol Reagent following the manufacturer’s instructions. The concentration and purity of RNA were measured spectrophotometrically at 260 and 280 nm with NanoDrop 2000 (Thermo Fisher Scientific). cDNA was synthesized from 1μg of total RNA in a 20μl reaction mixture using a High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor. The mixture was incubated at 25˚C for 10 minutes, 37˚C for 120 minutes, and 85˚C for 5 minutes. Veriquest SYBR green master mix was used for Real-time PCR in an Eppendorf Thermal Cycler. The reaction mixture was incubated at 95˚C for 10 minutes and cycled 40 times from 95˚C for 15 seconds to 60˚C for 1 minute. The primers used for qRT-PCR are shown in Table 1. All PCR data were normalized to GAPDH using the Double Delta CT Value method.

Statistical analysis

All measurements were performed in triplicate wells and data collected from at least three independent experiments are presented as means ± SEM. Results were analyzed by t-test or one-way analysis of variance (ANOVA) followed by Dunnett post hoc test for comparisons to a single control or Tukey post hoc test for multiple comparisons between groups. A P value less

| Genes         | Accession # | Forward (5’–3’)               | Reverse (5’–3’)               |
|---------------|-------------|--------------------------------|--------------------------------|
| MRP1, canine  | NM_001002971.1 | GCCCTCGCTCTCCCTCTTCTAC         | GGGTTTGGCCCAACCTTCTT          |
| MRP4, canine  | NM_001197174.1 | ATCTCTGTGGCTCTGCCAGCAGA       | GGTGACAAATCTGGCGCGGTA         |
| GAPDH, canine | AB038240.1  | GGGGGGCAAGGCGGGGCTCATAT      | CTTCTCCAGGCGGAGGTACAG        |
| MRP1, human   | L05628.1    | CTCCTCCGCTCTTCATCCATTCC      | TCTCGGTAGCAGCGCGAGTTCT       |
| MRP4, human   | CTGTAAGCAGCGAGGTGAGC     | CTTCTCCAGGCGGAGGTACAG        |
| GAPDH, human  | BC023632.2  | GGGAGCCAAAGGTTGACATC         | GACGGCTGCTTCACCCACCTTCTT    |

Table 1. Primer sequences for qRT-PCR.
than 0.05 was considered statistically significant (*P < 0.05, **P < 0.01 and ***P < 0.001). All analyses were performed with Prism 7 (Graph Pad, San Diego, CA).
A
mRNA expression of Canine/Human MRP1/4 in MDCKII-MRP1/4 cells

- Canine
- Human

B
3H-benzylpenicillin uptake in MDCKII-MRP1 cells

C
3H-benzylpenicillin uptake in MDCKII-MRP4 cells
Results

Wild-type MDCKII (WT) is a canine epithelial cell line which expresses MRP1, MRP2 and MRP5 [38] and our qRT-PCR data showed that it also expresses MRP4 (Fig 1A). The cellular uptake of $^3$H-benzylpenicillin was examined with and without non-selective MRP inhibitor (MK571), selective MRP1 inhibitor (reversan) and MRP4 inhibitor (ceefourin 1). Compared to control, 10 μM MK571, 2.5 μM reversan and 10 μM ceefourin 1 significantly increased $^3$H-benzylpenicillin uptake in MDCKII-WT cells by 2.94 ± 0.06, 1.75 ± 0.12 and 2.07 ± 0.05 fold, respectively (Fig 1B). These results suggest that benzylpenicillin is a MRP1 and MRP4 substrate in these canine cells.

MDCKII-MRP1 and MDCKII-MRP4 are MDCKII cell lines overexpressing human MRP1 and MRP4, which were 23.9 and 8 times higher than canine MRP1 and MRP4, respectively (Fig 2A). As shown in Fig 2B and 2C, $^3$H-benzylpenicillin uptake was increased 2.35 ± 0.18 and 3±0.11 fold by 10μM MK571 and 2.5μM reversan in MDCKII-MRP1 cells, and increased 2.87 ±0.14 and 2.63±0.09 fold by 10μM MK571 and 10μM ceefourin 1 in MDCKII-MRP4 cells, compared to control, indicating benzylpenicillin is also a substrate of human MRP1 and MRP4.

Hep G2 is a cell line from human hepatocellular carcinoma. According to prior reports, Hep G2 cells express MRP1, MRP2 and MRP3 [39, 40]. Our qRT-PCR result showed that Hep G2 cells also express MRP4 (Fig 3A). $^3$H-benzylpenicillin uptake in Hep G2 cells was enhanced 1.85±0.03, 1.37±0.02 or 1.92±0.03 fold when 10μM MK571, 2.5μM reversan or 10μM ceefourin 1 was present, respectively (Fig 3B).

hCMEC/D3 is a human cerebral microvascular endothelial cell line. Prior studies have shown MRP1, MRP2 and MRP4 expression in hCMEC/D3 cells[41, 42]. However, while qRT-PCR assay confirmed MRP1 expression in the current study, MRP4 was not detected (Fig 4A). Compared to control, $^3$H-benzylpenicillin uptake in hCMEC/D3 cells was increased 1.24 ±0.02 and 1.11±0.02 fold by 10μM MK571 and 2.5μM reversan, respectively (Fig 4B). Overall, results from Hep G2 and hCMEC/D3 cells provided more evidence that benzylpenicillin is a substrate of endogenous human MRP1 and MRP4.

Discussion

Benzylpenicillin, a beta-lactam antibiotic, has been used to treat bacterial infections, including those of the brain such as neonatal purulent meningitis. ABC efflux transporters P-gp, BCRP and MRPs are abundantly expressed at the BBB. They have a wide range of substrates including many therapeutic drugs, such as antibiotics and anticancer agents, and restrict those drugs from entering brain. It is very controversial and contradictory whether benzylpenicillin can enter brain and whether ABC transporters are involved in benzylpenicillin efflux transport. A previous study has suggested that benzylpenicillin enters brain freely [43] but Rousselle et al. found that benzylpenicillin can barely cross BBB and this can be significantly changed after coupling with SynB1 vector[26]. A study by Poelarends et al. have shown that benzylpenicillin and ampicillin are P-gp substrates after examining the effect of LmrA (a structural and functional homolog of human P-gp) expression on the relative antibiotic resistance of E. Coli CS1562 [28]. However, we have reported in our previous study that BCRP, but not P-gp, is involved in benzylpenicillin efflux transport in human. Results from the current study showed
Fig 3. mRNA expression of MRP transporters in Hep G2 cells (A) and [3H]benzylpenicillin uptake in Hep G2 cells with and without inhibitors (B). Values are means +/- S.E., n = 3, each performed in triplicate. *** indicate significant differences from comparison between different cells at the P<0.001 level.

https://doi.org/10.1371/journal.pone.0225702.g003
Fig 4. mRNA expression of MRP transporters in hCMEC/D3 cells (A) and [3H]benzylpenicillin uptake in hCMEC/D3 cells with and without 10μM MK 571 and 2.5μM reversan(B). Values are means +/- S.E., n = 3–6, each performed in triplicate. ** and *** indicate significant differences from comparison between different cells at the P<0.01 and P<0.001 levels, respectively.

https://doi.org/10.1371/journal.pone.0225702.g004
that inhibiting MRP1 and MRP4 in MDCKII-MRP1 and MDCKII-MRP4 cells with selective or non-selective inhibitors significantly increased benzylpenicillin amount in the cells. Similar results were found in Hep G2 (a cell line from human hepatocellular carcinoma) and hEMEC/D3 (a human cerebral microvascular endothelial cell line) cells. All of the results from the current study indicate that benzylpenicillin is also a substrate of human MRP1 and MRP4.

MRP1 and MRP4 are structurally close and their expression in human brain capillary endothelial cells, astrocytes, microglia and choroid plexus (which form the blood-CSF barrier) are well documented. They have been demonstrated to be associated with brain tumor resistance and also mediate efflux transport of a wide range of drugs such as glutathione, glucuronide, sulfate conjugates, immunosuppressants, HIV protease inhibitors, organic anions, prostaglandins and nucleoside analogs[4, 6]. In this study, we found that that MRP1 and MRP4 are also involved in antibiotic efflux transport.

Among ABC efflux transporters, MRPs are the largest group, consisting of 13 subfamily members [4, 6]. Besides MRP1 and MRP4, MRP2, MRP3 and MRP5 are also expressed in human brain capillary endothelial cells [4]. It is still unknown if other MRP transporters are involved in benzylpenicillin efflux transport, and this needs to be investigated in further studies. Furthermore, all beta-lactam antibiotics have a beta-lactam ring in their molecular structure and it is possible that other beta-lactam antibiotics are also substrates of human MRP1 and MRP4, because of their structural similarity. This also needs further studies.

ABC efflux transporters play a very important role at BBB in protecting the brain but, at the same time, they are an obstacle for therapeutic agents entering the brain. Therefore, there has been great interest in modulating ABC transporters at the BBB in order to increase brain protection (up-regulating ABC transporters) or improve drug delivery to the brain (inhibiting ABC transporters)[18, 19, 44, 45].

In summary, we found in this study that benzylpenicillin is a substrate of MRP1 and MRP4 in human and inhibiting these two transporters, plus BCRP, could be a new strategy to increase benzylpenicillin entering into brain to treat infection.

**Supporting information**

**S1 Table. Data for Fig 1.** A) Raw data on mRNA expression of canine MRP1 and MRP4 in MDCKII-WT cells (delta delta CT) used for Fig 1A and 1B) Data of [3H]-benzylpenicillin uptake in MDCKII-WT cells (% of Control) used for Fig 1B along with the raw data. (XLSX)

**S2 Table. Data for Fig 2.** A) Raw data on mRNA expression of Canine/Human MRP1/4 in MDCKII-MRP1/4 cells (delta delta CT) used for Fig 2A. B) Data of [3H]-benzylpenicillin uptake in MDCKII-MRP1 cells (% of Control) used for Fig 2B and 2C) Data of [3H]-benzylpenicillin uptake in MDCKII-MRP4 cells (% of Control) used for Fig 2C. (XLSX)

**S3 Table. Data for Fig 3.** A) Raw data on mRNA expression of Human MRP1 and MRP4 in Hep G2 cells (delta delta CT) used for Fig 3A and 3B) Data of [3H]-benzylpenicillin uptake in Hep G2 cells (% of Control) used for Fig 3B. (XLSX)

**S4 Table. Data for Fig 4.** A) Raw data on mRNA expression of Human MRP1 and MRP4 in hCMEC/D3 cells (delta delta CT) used for Fig 4A and 4B) Data of [3H]-benzylpenicillin uptake in hCMEC/D3 cells (% of Control) used for Fig 4B. (XLSX)
Acknowledgments

This work was supported by Programs of Scientific and Technological Talent Development/Ten-Hundred-Thousand Talent, Health Bureau of Kunming City, grant 2016-SW-(G)-19 and by Motor City Golf Classic grant from the Department of Neurosurgery, University of Michigan Medical School.

Author Contributions

Conceptualization: Yangfang Li, Richard F. Keep, Jianming Xiang.

Data curation: Jianming Xiang.

Formal analysis: Richard F. Keep, Jianming Xiang.

Funding acquisition: Xiaofen Zhao, Yangfang Li, Kun Du, Yuqin Wu, Ling Liu, Shan Cui, Yan Zhang, Jin Gao, Jianming Xiang.

Investigation: Xiaofen Zhao, Jianming Xiang.

Methodology: Richard F. Keep, Jianming Xiang.

Project administration: Yangfang Li, Jianming Xiang.

Supervision: Jianming Xiang.

Validation: Jianming Xiang.

Visualization: Jianming Xiang.

Writing – original draft: Xiaofen Zhao, Jianming Xiang.

Writing – review & editing: Xiaofen Zhao, Yangfang Li, Kun Du, Yuqin Wu, Ling Liu, Shan Cui, Yan Zhang, Jin Gao, Richard F. Keep, Jianming Xiang.

References

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. [Review] [168 refs].
2. Obermeier B, Verma A, Ransohoff RM. The blood-brain barrier. Handbook of clinical neurology. 2016; 133:39–59. Epub 2016/04/27. https://doi.org/10.1016/B978-0-444-63432-0.00003-7 PMID: 27112670.
3. Serlin Y, Shelef I, Knyazer B, Friedman A. Anatomy and physiology of the blood-brain barrier. Seminars in cell & developmental biology. 2015; 38:2–6. Epub 2015/02/15. https://doi.org/10.1016/j.semcdb.2015.01.002 PMID: 25681530; PubMed Central PMCID: PMC4397166.
4. Hartz AM, Bauer B. ABC transporters in the CNS—an inventory. Curr Pharm Biotechnol. 2011; 12(4):656–73. Epub 2010/12/02. https://doi.org/10.2174/138161211795164020 PMID: 21118088.
5. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx: the journal of the American Society for Experimental NeuroTherapeutics. 2005; 2(1):86–98. Epub 2005/02/18. https://doi.org/10.1602/neurorx.2.1.86 PMID: 15717060; PubMed Central PMCID: PMC539326.
6. Mahringer A, Fricker G. ABC transporters at the blood-brain barrier. Expert opinion on drug metabolism & toxicology. 2016; 12(5):499–508. Epub 2016/03/22. https://doi.org/10.1517/17425255.2016.1168804 PMID: 26998936.
7. Agarwal S, Hartz AM, Elmquist WF, Bauer B. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Current pharmaceutical design. 2011; 17(26):2793–802. Epub 2011/08/11. https://doi.org/10.2174/13816121179744016 PMID: 21827403; PubMed Central PMCID: PMC3269897.
8. Borst P, Schinkel AH. P-glycoprotein ABCB1: a major player in drug handling by mammals. The Journal of clinical investigation. 2013; 123(10):4131–3. Epub 2013/10/03. https://doi.org/10.1172/JCI70430 PMID: 24084745; PubMed Central PMCID: PMC3784548.
9. Eilers M, Roy U, Mondal D. MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells. Experimental biology and medicine (Maywood, NJ). 2008; 233(9):1149–60. Epub 2008/06/07. https://doi.org/10.3181/0802-rm-59 PMID: 18535159; PubMed Central PMCID: PMC2575034.

10. Iorio AL, da Ros M, Fantappie O, Lucchesi M, Facchini L, Stival A, et al. Blood-Brain Barrier and Breast Cancer Resistance Protein: a limit to the therapy of CNS tumors and neurodegenerative diseases. Anticancer agents in medicinal chemistry. 2015. Epub 2015/11/21. https://doi.org/10.2174/187152061666615120121928 PMID: 26584727.

11. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug metabolism reviews. 2002; 34(1–2):47–54. Epub 2002/05/09. https://doi.org/10.1081/dmr-120001389 PMID: 11996011.

12. Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Molecular cancer therapeutics. 2010; 9(2):319–26. Epub 2010/01/28. https://doi.org/10.1158/1535-7163.MCT-09-0663 PMID: 20103600.

13. Potschka H, Fedrowitz M, Loscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. The Journal of pharmacology and experimental therapeutics. 2003; 306(1):124–31. Epub 2003/03/29. https://doi.org/10.1124/jpet.120.049858 PMID: 12663688.

14. Shen S, Zhang W. ABC transporters and drug efflux at the blood-brain barrier. Rev Neurosci. 2010; 21(1):29–53. Epub 2010/05/13 06:00. https://doi.org/10.1515/rneuro.2010.21.1.29 PMID: 20458886.

15. Acharya P, Tran TT, Polli JW, Ayrton A, Ellens H, Bentz J. P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1- MDCKII cells has more than one efflux pathway with cooperative binding sites. Biochemistry. 2006; 45(51):15505–19. https://doi.org/10.1021/bi060593b PMID: 17176072.

16. Azad TD, Pan J, Connolly ID, Remington A, Wilson CM, Grant GA. Therapeutic strategies to improve drug delivery across the blood-brain barrier. Neurosurgical focus. 2015; 38(3):E9. Epub 2015/03/03. https://doi.org/10.3171/2014.12.FOCUS14758 PMID: 25727231; PubMed Central PMCID: PMC4493051.

17. Fricker G, Miller DS. Modulation of drug transporters at the blood-brain barrier. [Review] [61 refs].

18. Hartz AM, Bauer B. Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy. Molecular interventions. 2010; 10(5):293–304. Epub 2010/11/04. https://doi.org/10.1124/mi.10.5.6 PMID: 20528866.

19. Miller DS. Regulation of ABC transporters blood-brain barrier: the good, the bad, and the ugly. Advances in cancer research. 2015; 125:43–70. Epub 2015/02/03. https://doi.org/10.1016/bs.acr.2014.10.002 PMID: 25640266.

20. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Critical care medicine. 2009; 37(6):2071–8. Epub 2009/04/23. https://doi.org/10.1097/CCM.0b013e3181a054d PMID: 19384201.

21. Tomasz A. The mechanism of the irreversible antimicrobial effects of penicillins: how the beta-lactam antibiotics kill and lyse bacteria. Annual review of microbiology. 1979; 33:113–37. Epub 1979/01/01. https://doi.org/10.1146/annurev.mi.33.100179.000553 PMID: 40528.

22. Ramos SR, Feferbaum R, Manissadjian A, Vaz FA. [Neonatal bacterial meningitis: etiologic agents in 109 cases during a 10 year period]. Arquivos de neuro-psiquiatria. 1992; 50(3):289–94. Epub 1992/09/01. https://doi.org/10.1590/s0004-282x1992000300005 PMID: 1308405.

23. Zhu ML, Mai JY, Zhu JH, Lin ZL. [Clinical analysis of 31 cases of neonatal purulent meningitis caused by Escherichia coli]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics. 2012; 14(12):910–2. Epub 2012/12/14. PMID: 23234776.

24. Norrby SR. Problems in evaluation of adverse reactions to beta-lactam antibiotics. Reviews of infectious diseases. 1986; 8 Suppl 3:S358–70. Epub 1986/07/01. https://doi.org/10.1093/clinids/8.suppl_3.s358 PMID: 3529328.

25. Schlamser SE. Neurotoxicity of beta-lactam antibiotics. Experimental kinetic and neurophysiological studies. Scandinavian journal of infectious diseases Supplementum. 1988; 55:1–61. Epub 1988/01/01. https://doi.org/10.3109/inf.1988.suppl-55.01 PMID: 3241957.

26. Rousselle C, Clair P, Tensmamani J, Scherrmann JM. Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy. Journal of drug targeting. 2002; 10(4):309–15. Epub 2002/08/08. https://doi.org/10.1080/106118620003188 PMID: 12164379.

27. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene. 2003; 22(47):7468–85. Epub 2003/10/25. https://doi.org/10.1038/sj.onc.1206948 PMID: 14576852.
28. Poelarends GJ, Mazurkiewicz P, Putman M, Cool RH, Veen HW, Konings WN. An ABC-type multidrug transporter of Lactococcus lactis possesses an exceptionally broad substrate specificity. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 2000; 3(6):330–4. Epub 2000/08/11. https://doi.org/10.1054/drup.2000.0173 PMID: 11498401.

29. Seelig A. How does P-glycoprotein recognize its substrates? International journal of clinical pharmacology and therapeutics. 1998; 36(1):50–4. Epub 1998/02/26. PMID: 9476149.

30. Sirarheyeva A, Lopez JJ, Giaibitz C. Localization of multidrug transporter substrates within model membranes. Biochemistry. 2006; 45(19):6203–11. Epub 2006/05/10. https://doi.org/10.1021/bi0524870 PMID: 16681393.

31. Choi MK, Kim H, Han YH, Song IS, Shim CK. Involvement of Mrp2/MRP2 in the species different excretion route of benzylpenicillin between rat and human. Xenobiotica. 2009; 39(2):171–81. Epub 2009/03/04. https://doi.org/10.1080/009589608026242256 PMID: 19255943.

32. Li Y, Wu Q, Li C, Liu L, Du K, Shen J, et al. Role of Human Breast Cancer Related Protein versus P-Glycoprotein as an Efflux Transporter for Benzylpenicillin: Potential Importance at the Blood-Brain Barrier. PLoS one. 2016; 11(6):e0157576. Epub 2016/06/15. https://doi.org/10.1371/journal.pone.0157576 PMID: 27306692; PubMed Central PMCID: PMC4907523.

33. Helms HC, Hersorn M, Kuhlmann LB, Badolo L, Nielsen CU, Brodin B. An electrically tight in vitro blood-brain barrier model displays net brain-to-blood efflux of substrates for the ABC transporters, P-gp, Bcrp and Mdr-1. The AAPS journal. 2014; 16(5):1046–55. Epub 2014/06/18. https://doi.org/10.1208/s12246-014-9628-1 PMID: 24934296; PubMed Central PMCID: PMC4174044.

34. Tivnan A, Zakaria Z, O’Leary C, Kogel D, Pokorny JL, Sarkaria JN, et al. Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme. Frontiers in neuroscience. 2015; 9:218. Epub 2015/07/03. https://doi.org/10.3389/fnins.2015.00218 PMID: 26138682; PubMed Central PMCID: PMC4468687.

35. Cheung L, Flemming CL, Watt F, Masada N, Yu DM, Huynh T, et al. Role of Human Breast Cancer Related Protein versus P-Glycoprotein in the Mechanism of Toxicity and Resistance of Paclitaxel in Breast Cancer Cells. PLoS ONE. 2015; 10(3):e0119502. Epub 2015/03/18. https://doi.org/10.1371/journal.pone.0119502 PMID: 25781341; PubMed Central PMCID: PMC4364073.

36. Rigalli JP, Ciriaci N, Arias A, Ceballos MP, Villaneuva SS, Luquita MG, et al. Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity. PLoS one. 2015; 10(3):e0119502. Epub 2015/03/18. https://doi.org/10.1371/journal.pone.0119502 PMID: 25781341; PubMed Central PMCID: PMC4364073.

37. Dauchy S, Miller F, Couraud PO, Weaver RJ, Weksler B, Romero IA, et al. Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochemical pharmacology. 2009; 77(5):897–909. Epub 2008/12/02. https://doi.org/10.1016/j.bcp.2008.11.001 PMID: 19041851.

38. Ohtsuki S, Ikeda C, Uchida Y, Sakamoto Y, Miller F, Glacial F, et al. Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell hCMEC/D3 as a human blood-brain barrier model. Molecular pharmaceutics. 2013; 10(1):289–96. Epub 2012/11/10. https://doi.org/10.1021/mp3004308 PMID: 23137377.

39. Schlamser SE, Cars O, Norby SR. Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother. 1991; 27(4):405–25. Epub 1991/04/01. https://doi.org/10.1093/jac/27.4.405 PMID: 1856121.
44. Oberoi RK, Parrish KE, Sio TT, Mittapalli RK, Elmquist WF, Sarkaria JN. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro-oncology. 2016; 18(1):27–36. Epub 2015/09/12. https://doi.org/10.1093/neuonc/nov164 PMID: 26359209; PubMed Central PMCID: PMC4677418.

45. Pardridge WM. Blood-brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery. Expert opinion on therapeutic targets. 2015; 19(8):1059–72. Epub 2015/05/06. https://doi.org/10.1517/14728222.2015.1042364 PMID: 25936389.